Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.53 |
| ▸ | RAB9A | P51151 | 9/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29968159 | 1.00 | NPC1 (0.53) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL6687497 | 0.85 | MAPT (0.52) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL29968689 | 0.85 | MAPT (0.52) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL29968283 | 0.85 | MAPT (0.49) | KMT2AMEN1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL6687417 | 0.85 | MAPT (0.49) | KMT2AMEN1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL29968854 | 0.83 | MAPT (0.51) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL6692431 | 0.83 | CCR3 (0.48) | KMT2AMEN1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL6686800 | 0.83 | MAPT (0.51) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL6689954 | 0.82 | MAPT (0.49) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL6684975 | 0.81 | NPSR1 (0.48) | NPC1RAB9AKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-25 | — | — | US | claimed |
| WO-2004087685-A2 | PHOSPHOLIPASE C INHIBITORS FOR USE IN TREATING INFLAMMATORY DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-10-14 | — | — | WO | claimed |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | disclosed |
| CN-117999073-A | Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway | 慢性呼吸道治疗有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | NPC1 631/4885RAB9A 2434/4885KMT2A 3828/4885 |
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | PLA2G4C, PLA2G4B, PLA2G5 | NPC1 1212/4885RAB9A 1555/4885KMT2A 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.